Hansa Biopharma AB

5 trials 1 recruiting Commercial sponsor Merged from 2 name variants

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

14 Countries active

11 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 3 Phase II: 2

Oversight events:

1 serious breach 2 temporary halts across 2 trials

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Kidney transplant rejection 3

Top IMPs

IMLIFIDASE 4 1,3,5-TRIS(6-METHYLPYRIDIN-2-YLOXY)BENZENE 1

All trials

5 total

Desensitisation with imlifidase prior to kidney transplant in highly sensitised children Recruiting

2022-500230-28-00 Phase II 4 countries IMLIFIDASE
A long-term follow-up trial of patients previously treated with imlifidase prior to kidney transplantation and a non-comparative transplante… Ended

2022-502727-21-00 Phase III 8 countries IMLIFIDASE
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Participants with Moderate to Severe Ulcerative Colitis Ended

2022-503005-38-00 Phase II 3 countries 1,3,5-TRIS(6-METHYLPYRIDIN-2-YLOXY)BENZENE
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th… Ended

2022-500121-33-01 Phase III 12 countries IMLIFIDASE
Study in highly sensitised kidney transplant patients with a high degree of antibodies against the donor's kidney to see the efficacy and sa… Ended

2024-511810-18-00 Phase III 10 countries IMLIFIDASE

Showing 1–5 of 5 trials

← All sponsors A–Z